Nutritional status and quality of life with or without Ninjin'yoeito during first-line chemotherapy for metastatic colorectal cancer: an exploratory, open-label randomized phase II trial
In an exploratory randomized phase II trial for metastatic colorectal cancer, the addition of the Kampo medicine Ninjin'yoeito to first-line chemotherapy did not significantly improve the primary endpoints of nutritional status or severe nonhematological adverse events, though exploratory analyses suggested potential benefits in body mass index maintenance and appetite alongside higher insomnia scores.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer treatment is a battle fought on two fronts: the medical effort to destroy the tumor and the body's struggle to survive the assault. For patients with metastatic colorectal cancer, where the disease has spread beyond the colon, standard care involves powerful chemotherapy drugs that can be as exhausting as they are effective. These treatments often strip away appetite, drain energy, and cause weight loss, leading to a state of malnutrition that makes it harder for the body to tolerate the medicine. In Japan, doctors have long turned to a traditional herbal mixture called Ninjin'yoeito to help patients manage these specific side effects, aiming to restore vitality and improve how they feel day to day. The question researchers have long asked is whether this ancient remedy can actually protect a patient's nutritional health and quality of life when used alongside modern chemotherapy, or if its benefits are merely a matter of feeling better without changing the physical outcome.
To find a definitive answer, a team of researchers across fifteen hospitals in Japan launched a clinical trial involving patients with unresectable metastatic colorectal cancer. These patients were scheduled to receive a standard first-line treatment consisting of a combination of chemotherapy drugs and a targeted therapy agent. The study divided the participants into two groups: one group received the standard treatment alone, while the other received the same treatment plus the herbal mixture Ninjin'yoeito. The researchers set out to measure two main things: whether the herbal supplement helped maintain the patients' nutritional status, assessed by a score calculated from blood tests, and whether it reduced the frequency of severe side effects that were not related to blood cell counts. They also tracked body mass index, quality of life, and how long the cancer remained under control.
The study was designed to enroll one hundred and fifty patients, but the recruitment process moved much slower than anticipated, partly due to the global pandemic. Consequently, the trial was stopped early after only seventy-eight people had been randomized. Of these, seventy-four were included in the final analysis, with thirty-nine receiving the herbal supplement and thirty-five receiving only the standard care. When the researchers compared the two groups, they found that the herbal mixture did not significantly change the primary outcomes they had set out to measure. The scores reflecting nutritional status, which rely on levels of albumin, cholesterol, and lymphocytes in the blood, remained statistically similar between the two groups. Similarly, the rate of severe non-blood-related side effects, such as organ stress or severe fatigue, was nearly identical, with about one-quarter of the supplement group and one-fifth of the control group experiencing these events.
However, the study did uncover some interesting secondary signals that suggest the herbal mixture might offer specific benefits, even if it did not alter the main statistical endpoints. Patients who took the supplement maintained their body mass index better than those who did not; while the control group's weight remained stable or dipped slightly, the supplement group saw a small but measurable increase in their body mass index over the course of treatment. In terms of how patients felt, the group taking the supplement reported significantly less loss of appetite, a crucial factor for maintaining strength during chemotherapy. They also reported fewer financial difficulties, likely because they felt better and perhaps required fewer resources to manage their symptoms. Yet, this group also reported higher levels of insomnia, a side effect that remained significant even when the researchers adjusted their analysis for missing data.
The researchers were careful to note that because the study ended early with fewer participants than planned, these positive findings regarding weight and appetite should be viewed as hypotheses for future research rather than confirmed facts. The study did not find any difference in how long the cancer stayed in check between the two groups, nor did it prove that the herbal mixture prevented severe side effects overall. While the supplement appeared to help patients keep their weight up and eat better, the study could not determine if this was due to improved muscle mass, changes in body fat, or simply fluid retention. The trial serves as a clear example of how science works: it tested a long-held belief with rigorous methods, found that the main goals were not met, but identified specific areas where the treatment might help, pointing the way for larger, more powerful studies to confirm whether Ninjin'yoeito can truly be a helpful companion for cancer patients.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.